Cited by 28Circadian rhythm and melatoninGut microbiota and healthEstrogen and related hormone effects

A New Paradigm in the Relationship between Melatonin and Breast Cancer: Gut Microbiota Identified as a Potential Regulatory Agent

Open access
Laborda-Illanes, Aurora, Sánchez-Alcoholado, Lidia, Boutriq, Soukaina, Plaza-Andrades, Isaac, Peralta-Linero, Jesús, Alba, Emilio, González-González, Alicia, Queipo-Ortuño, María Isabel·2021·Cancers

Abstract

In this review we summarize a possible connection between gut microbiota, melatonin production, and breast cancer. An imbalance in gut bacterial population composition (dysbiosis), or changes in the production of melatonin (circadian disruption) alters estrogen levels. On the one hand, this may be due to the bacterial composition of estrobolome, since bacteria with β-glucuronidase activity favour estrogens in a deconjugated state, which may ultimately lead to pathologies, including breast cancer. On the other hand, it has been shown that these changes in intestinal microbiota stimulate the kynurenine pathway, moving tryptophan away from the melatonergic pathway, thereby reducing circulating melatonin levels. Due to the fact that melatonin has antiestrogenic properties, it affects active and inactive estrogen levels. These changes increase the risk of developing breast cancer. Additionally, melatonin stimulates the differentiation of preadipocytes into adipocytes, which have low estrogen levels due to the fact that adipocytes do not express aromatase. Consequently, melatonin also reduces the risk of breast cancer. However, more studies are needed to determine the relationship between microbiota, melatonin, and breast cancer, in addition to clinical trials to confirm the sensitizing effects of melatonin to chemotherapy and radiotherapy, and its ability to ameliorate or prevent the side effects of these therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers13133141

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 108 · Cited by 28

Research works printed but not linked: 1

  1. [46]Cos S. González A. Alvarez Garcia V. Alonso-Gonzalez C. Martinez-Campa C. Melatonin and Breast Cancer: Selective Estrogen Enzyme Modulator Adv. Cancer Drug Targets 2012 1 207 237 19075592

Authors
Laborda-Illanes, A., Sánchez-Alcoholado, L., Boutriq, S., Plaza-Andrades, I., Peralta-Linero, J., Alba, E., González-González, A., & Queipo-Ortuño, M. I.
Affiliations
  • Instituto de Investigación Biomédica de Málaga (ES)
  • Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA)-CIMES-UMA, 29010 Málaga, Spain
  • Centro de Investigación Biomédica en Red de Cáncer (ES)
Corresponding author
  • Alba, Emilio
  • González-González, Alicia
Venue
Cancers
Publisher
MDPI AG
Published
2021-06-23
Volume
13
Issue
13
Pages
3141
ISSN
2072-6694 (ISSN-L)
OpenAlex
W3175171549
Cited by
28
References
108
Citations by year
2026: 4 · 2025: 5 · 2024: 7 · 2023: 3 · 2022: 8 · 2021: 1
FWCI
0.61
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Consejería de Salud de la Junta de Andalucía (PE-0106-2019)
  • Fundación Unicaja (C19047-2018)
  • UMA-FEDER (UMA18-FEDERJA-042)
  • Consejería de Salud (C-0030-2018), Junta de Andalucía (Regional “Nicolas Monardes” research program)
  • ALIANZA MIXTA EN RED ANDALUCÍA-ROCHE EN ONCOLOGÍA MÉDICA DE PRECISIÓN (INVESTIGACIÓN BÁSICA/TRASLACIONAL) (-)
  • Consejería de Salud y Familia (co-funded by the Fondo Europeo de Desarrollo Regional-FEDER) (Predoctoral grant (PE-0106-2019))
  • ISCIII and co-funded by the Fondo Europeo de Desarrollo Regional-FEDER (Predoctoral grant PFIS-ISCIII (FI19-00112))
  • ISCIII, co-funded by the Fondo Europeo de Desarrollo Regional-FEDER (“Miguel Servet Type II” program (CPI13/00003))
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Circadian rhythm and melatonin
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
Keywords
melatonin, breast cancer, gut microbiota, dysbiosis, estrobolome, beta-glucuronidase, estrogen metabolism, circadian rhythm disruption, kynurenine pathway, tryptophan metabolism, adipogenesis, aromatase, antiestrogenic effects

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review